Emovo Care Secures Key Funding to Advance Robotic Hand Exoskeleton for Home Rehabilitation
Emovo Care, a Swiss medical technology company developing robotic orthoses to help people with hand motor impairments regain movement at home, has continued to attract investor support as it advances its mission to commercialize assistive robotics. Founded in 2020 as a spin‑off of research conducted at the École polytechnique fédérale de Lausanne (EPFL), the Lausanne‑based start‑up has secured funding through multiple early‑stage rounds and institutional support to develop its core exoskeleton technology and scale its operations.
Since its inception, Emovo Care has participated in at least three distinct funding events. Its earliest financial backing came in the form of a pre‑seed grant from Venture Kick, a Swiss start‑up initiative that awarded the company CHF 150,000 to support development of its initial prototype and prepare for commercialization. This funding was aimed at accelerating development of Emovo’s lightweight robotic hand orthosis technology that enables users to actively open and close their hands, addressing a critical need for individuals with motor impairments due to neurological conditions like stroke.
Following this early support, Emovo Care attracted further investor interest. The company has completed multiple seed funding rounds, with its most recent round closing on June 18, 2024. In these rounds, SICTIC (Swiss ICT Investor Club) emerged as one of the lead investors in the company’s financing activities. SICTIC is a prominent early‑stage investment network in Switzerland that connects tech startups with business angel investors, providing seed capital and strategic guidance as companies scale.
Another notable investor backing Emovo Care in its seed round is Next Humanity Ventures, a venture group focused on supporting impactful technology ventures. Participation from Next Humanity Ventures underscores growing confidence in Emovo’s potential to create breakthrough solutions in assistive robotics and neurorehabilitation.
In addition to private investment, Emovo Care has benefited from ecosystem support. Throughout 2024, the company was among several start‑ups that received continued backing from the Biopôle Start‑up Fund, a programme that provides early‑stage companies up to CHF 90,000 in funding and access to investment readiness training. This support is designed to strengthen young companies’ capacity to attract future capital and improve their business foundations. Emovo Care securing a second year of support under this fund reflects investor confidence in its ongoing development and market prospects.
Altogether, these funding injections helped Emovo Care progress beyond proof‑of‑concept and into regulatory and commercialization phases. Much of the funding has been directed toward obtaining quality management system certification and advancing toward broader market entry, including preparation for CE marking and scaling production capabilities. In late 2025, the company announced that its “Emovo Clinic” hand exoskeleton achieved CE marking, clearing a key regulatory hurdle for commercialization in the European Union.
Emovo Care’s investors bring a mix of financial backing and strategic support that is crucial for early‑stage medtech startups. Venture Kick’s early seed award connected the company to Switzerland’s deep ecosystem of technology accelerators and angel networks, while SICTIC’s involvement provided access to business angels and potential follow‑on funding. Next Humanity Ventures’ participation highlights broader interest from impact‑oriented venture groups in health and robotics technologies. The Biopôle Start‑up Fund’s support further underscores the role of public‑private initiatives in de‑risking early‑stage innovation and preparing ventures like Emovo Care for larger funding rounds.
As Emovo Care moves forward, its combination of private investment and support from innovation funds positions it well to bring its robotic hand exoskeleton to patients and providers. With its technology now certified for clinical and at‑home use in Europe and a funding base that includes both angel‑driven and venture‑oriented investors, Emovo Care is poised to deepen its impact in the assistive technology marketplace while pursuing further commercialization and growth opportunities.
